Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Ostarine
Also known as: MK-2866, Enobosarm, GTx-024
Ostarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Risk Level
Medium RiskDifficulty
Beginner| CAS Number | 841205-47-8 |
| Molecular Formula | C19H14F3N3O3 |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
Ostarine selectively binds to androgen receptors in muscle and bone tissue with minimal activity in prostate and sebaceous glands. It activates anabolic pathways similar to testosterone but with tissue-selective action, promoting lean mass accrual and bone mineral density.
Dosing Research
Clinical trials used 1-3 mg/day orally. Research community commonly references 10-25 mg/day. Cycles typically 8-12 weeks in research contexts. Half-life approximately 24 hours.
Side Effects & Risks
Dose-dependent suppression of natural testosterone. HDL cholesterol reduction observed in trials. Liver enzyme elevations possible at higher doses. Long-term safety data beyond 12 weeks is limited.
Research Studies
Related compounds
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Andarine
SARMAndarine was one of the first SARMs developed by GTx Inc. It showed promise for muscle wasting and osteoporosis in preclinical trials but development was halted due to visual side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.